One-year outcomes in schizophrenia after switching from typical antipsychotics to olanzapine in Japan: an observational study

References

• BuchananRWKreyenbuhlJKellyDLThe 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statementsSchizophr Bull2010361719319955390
   PubMed Web of Science ®Google Scholar
• Canadian Psychiatric AssociationClinical practice guidelines. Treatment of schizophreniaCan J Psychiatry20055013 Suppl 17S57S16529334
   PubMedGoogle Scholar
• FalkaiPWobrockTLiebermanJGlenthojBGattazWFMöllerHJWorld Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia. Part 1: acute treatment of schizophreniaWorld J Biol Psychiatry20056313219116173147
   PubMed Web of Science ®Google Scholar
• FalkaiPWobrockTLiebermanJGlenthojBGattazWFMöllerHJWorld Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia. Part 2: long-term treatment of schizophreniaWorld J Biol Psychiatry20067154016509050
   PubMed Web of Science ®Google Scholar
• LehmanAFLiebermanJADixonLBPractice guideline for the treatment of patients with schizophrenia, second editionAm J Psychiatry2004161Suppl 215615000267
   PubMed Web of Science ®Google Scholar
• LiebermanJAStroupTSMcEvoyJPEffectiveness of antipsychotic drugs in patients with chronic schizophreniaN Engl J Med2005353121209122316172203
   PubMed Web of Science ®Google Scholar
• ParkSRoss-DegnanDAdamsASSabinJKanavosPSoumeraiSBEffect of switching antipsychotics on antiparkinsonian medication use in schizophrenia: population-based studyBr J Psychiatry200518713714216055824
   PubMed Web of Science ®Google Scholar
• Liu-SeifertHAdamsDHKinonBJDiscontinuation of treatment of schizophrenic patients is driven by poor symptom response: a pooled post-hoc analysis of four atypical antipsychotic drugsBMC Med20053213016375765
   PubMed Web of Science ®Google Scholar
• BitterIChouJC-YUngvariGSPrescribing for inpatients with schizophrenia: an international multi-center comparative studyPharmacopsychiatry200336414314912905100
   PubMed Web of Science ®Google Scholar
• ChongMYTanCHFujiiSAntipsychotic drug prescription for schizophrenia in East Asia: rationale for changePsychiatry and Clin Neurosci20045816167
   PubMed Web of Science ®Google Scholar
• ShinfukuNTanC-HPharmacotherapy for schizophrenic inpatients in East Asia – changes and challengesInt Rev Psychiatry200820546046819012132
   PubMed Web of Science ®Google Scholar
• OshimaIMinoYInomataYHow many long-stay schizophrenia patients can be discharged in Japan?Psychiatry Clin Neurosci2007611717717239042
   PubMed Web of Science ®Google Scholar
• KuramochiMOnoHNakaharaNHealth outcome survey of olanzapine therapy in patients with schizophrenia: Analytical results of the post-marketing special survey of olanzapineJpn J Clin Psychopharmacol20091217189
   Google Scholar
• American Psychiatric AssociationDiagnostic and Statistical Manual of Mental Disorders DSM-IV4th edWashington, DCAmerican Psychiatric Association1994
   Google Scholar
• HaroJMKamathSAOchoaSThe Clinical Global Impression-Schizophrenia scale: a simple instrument to measure the diversity of symptoms present in schizophreniaActa Psychiatr Scand Suppl2003416162312755850
   PubMedGoogle Scholar
• KaySROplerLAFiszbeinAPositive and Negative Syndrome Scale (PANSS) User’s ManualNorth Tonawanda, NYMulti-Health Systems Inc2000
   Google Scholar
• The EuroQol GroupEuroQol – a new facility for the measurement of health-related quality of lifeHealth Policy199016319920810109801
   PubMed Web of Science ®Google Scholar
• PrietoLSacristánJAHormaecheaJACasadoABadiaXGómezJCPsychometric validation of a generic health-related quality of life measure (EQ-5D) in a sample of schizophrenic patientsCurr Med Res Opin200420682783515200739
   PubMed Web of Science ®Google Scholar
• HaroJMEdgellETNovickDEffectiveness of antipsychotic treatment for schizophrenia: 6-month results of the Pan-European Schizophrenia Outpatient Health Outcomes (SOHO) studyActa Psychiatr Scand2005111322023115701107
   PubMed Web of Science ®Google Scholar
• HaroJMNovickDSuarezDAlonsoJLépineJPRatcliffeMRemission and relapse in the outpatient care of schizophrenia: three-year results from the Schizophrenia Outpatient Health Outcomes studyJ Clin Psychopharmacol200626657157817110813
   PubMed Web of Science ®Google Scholar
• WHO Expert ConsultationAppropriate body-mass index for Asian populations and its implications for policy and intervention strategiesLancet2004363940315716314726171
   PubMed Web of Science ®Google Scholar
• StroupTSMcEvoyJPSwartzMSThe National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) project: schizophrenia trial design and protocol developmentSchizophr Bull2003291153112908658
   PubMed Web of Science ®Google Scholar
• Ascher-SvanumHStenslandMZhaoZKinonBJAcute weight gain, gender, and therapeutic response to antipsychotics in the treatment of patients with schizophreniaBMC Psychiatry20055315649317
   PubMed Web of Science ®Google Scholar
• Ascher-SvanumHStenslandMDKinonBJTollefsonGDWeight gain as a prognostic indicator of therapeutic improvement during acute treatment of schizophrenia with placebo or active antipsychoticJ Psychopharmacol200519Suppl 611011716280344
   PubMedGoogle Scholar
• SoniSDMallikAReedPGaskellKDifferences between chronic schizophrenic patients in the hospital and in the communityHosp Community Psychiatry19924312123312381360939
   PubMedGoogle Scholar
• NakanishiMSetoyaYKodakaMSymptom dimensions and needs of care among patients with schizophrenia in hospital and the communityPsychiatry Clin Neurosci200761549550117875027
   PubMed Web of Science ®Google Scholar
• NakanishiSKunugiHMurrayRMNojimaSOgawaTTakahashiTEffects of switching from conventional antipsychotics to risperidone in Japanese patients with chronic schizophreniaPsychiatry Clin Neurosci200660675175717109710
   PubMed Web of Science ®Google Scholar
• KanedaYKawamuraIFujiiAOhmoriTImpact of a switch from typical to atypical antipsychotic drugs on quality of life and gonadal hormones in male patients with schizophreniaNeuro Endocrinol Lett2004251–213514015159697
   PubMed Web of Science ®Google Scholar
• NovickDHaroJMSuarezDMarques-TeixeiraJNaberDClinical consequences of switching antipsychotic drugs in outpatients with schizophrenia: 36-month results from the European Schizophrenia Outpatient Health Outcomes studyInt Clin Psychopharmacol200823420320818545058
   PubMed Web of Science ®Google Scholar
• LuZHuJChenCKEffectiveness and safety of olanzapine in the treatment of schizophrenia among Asian patients switching from conventional antipsychoticsProg Neuropsychopharmacol Biol Psychiatry2007311324016843580
   PubMed Web of Science ®Google Scholar
• DossenbachMDyachkovaYPirildarSEffects of atypical and typical antipsychotic treatments on sexual function in patients with schizophrenia: 12-month results from the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) studyEur Psychiatry200621425125816530390
   PubMed Web of Science ®Google Scholar
• MontesJMCiudadAGascónJGómezJCSafety, effectiveness, and quality of life of olanzapine in first-episode schizophrenia: a naturalistic studyProg Neuropsychopharmacol Biol Psychiatry200327466767412787855
   PubMed Web of Science ®Google Scholar
• LeuchtSCorvesCArbterDEngelRRLiCDavisJMSecond-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysisLancet20093739657314119058842
   PubMed Web of Science ®Google Scholar
• StroupTSLiebermanJAMcEvoyJPResults of phase 3 of the CATIE schizophrenia trialSchizophr Res2009107111219027269
   PubMed Web of Science ®Google Scholar